Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 14/20 | 0.69 |
| ▸ | TGM2 | P21980 | 4/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124586 | 0.82 | CES1 (1.00) | CES1TGM2DNMT1 | |
| SCHEMBL29758460 | 0.82 | CES1 (1.00) | CES1TGM2DNMT1 | |
| SCHEMBL29443269 | 0.80 | TGM2 (0.50) | CES1TGM2MAOAMAOB | |
| SCHEMBL1398146 | 0.80 | TGM2 (0.50) | CES1TGM2MAOAMAOB | |
| SCHEMBL8573750 | 0.77 | CES1 (0.69) | CES1TGM2DNMT1BCHE | |
| SCHEMBL16419647 | 0.77 | CES1 (0.44) | CES1TGM2MAOAMAOBBCHE | |
| SCHEMBL6176815 | 0.77 | CES1 (0.69) | CES1TGM2DNMT1MAOAMAOB | |
| SCHEMBL8873852 | 0.76 | CES1 (0.88) | CES1TGM2DNMT1 | |
| SCHEMBL8873649 | 0.74 | TGM2 (0.48) | CES1TGM2MAOAMAOB | |
| SCHEMBL1398084 | 0.74 | CES1 (0.66) | CES1TGM2DNMT1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014023083-A1 | PI3Kδ INHIBITOR | 山东亨利医药科技有限责任公司 (CN) | 2014-02-13 | — | — | WO | disclosed |
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957481-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062817-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | TPMT, MALT1, THPO | CES1 3841/4885TGM2 1842/4885DNMT1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.